RxDoctor Payments Data

Maryam Somo, MD

Family Medicine · Owosso, MINPI 1437644127

Payments from drug & device makers

$788in general payments, 2019–2025

Across 17 payments — averaging $46.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$202
  • Johnson & Johnson$169
  • Neurocrine Biosciences, Inc.$91
  • Novo Nordisk$86
  • Amgen$79
  • Pfizer$62
  • plus $100 from 5 others

What the payments were for

  • Food & beverage$78199%
  • Education$71%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$788 in reported general payments places this provider in the 65th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$26,672
Medicare patients
112
Services billed
296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban26$40,278
MounjaroTirzepatide33$36,825
XareltoRivaroxaban14$17,550
TrulicityDulaglutide14$15,155
Spiriva RespimatTiotropium Bromide14$7,026
Rosuvastatin Calcium146$3,786
Levothyroxine Sodium270$3,761
Losartan Potassium259$3,470
Atorvastatin Calcium237$3,428
SymbicortBudesonide/Formoterol Fumarate11$2,480
Potassium Chloride95$2,250
Metoprolol Succinate94$2,050
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$2,042
Omeprazole125$2,009
LantusInsulin Glargine,hum.Rec.Anlog11$1,888

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$15$51,98047 claims
PfizerEliquis$62$40,27826 claims
Johnson & JohnsonXarelto$169$17,55014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Owosso

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →